User profiles for Yu Zhuang

Yu Zhuang

- Verified email at dlut.edu.cn - Cited by 1091

Yu Zhuang

- Verified email at my.cityu.edu.hk - Cited by 551

[HTML][HTML] Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized …

Y Yang, Z Wang, J Fang, Q Yu, B Han, S Cang… - Journal of Thoracic …, 2020 - Elsevier
Introduction Sintilimab, an anti–programmed death 1 antibody, plus pemetrexed and
platinum had revealed promising efficacy for nonsquamous NSCLC in a phase 1b study. We …

Measuring daily accessed street greenery: A human-scale approach for informing better urban planning practices

Y Ye, D Richards, Y Lu, X Song, Y Zhuang… - Landscape and Urban …, 2019 - Elsevier
The public benefits of visible street greenery have been well recognised in a growing
literature. Nevertheless, this issue was rare to be included into urban greenery and planning …

The origin of negative stacking fault energies and nano-twin formation in face-centered cubic high entropy alloys

YH Zhang, Y Zhuang, A Hu, JJ Kai, CT Liu - Scripta Materialia, 2017 - Elsevier
The secrets behind the exceptional mechanical properties of high entropy alloys (HEAs) at
cryogenic temperatures have drawn much attention in recent years. In this work, the negative …

[HTML][HTML] Resveratrol attenuates oxidative stress-induced intestinal barrier injury through PI3K/Akt-mediated Nrf2 signaling pathway

Y Zhuang, H Wu, X Wang, J He, S He… - Oxidative medicine and …, 2019 - hindawi.com
Oxidative stress is implicated in a wide range of intestinal disorders and closely associated
with their pathological processes. Resveratrol (RSV), a plant extract, plays a vital role in …

Conceptual design of the triple-column extractive distillation processes with single entrainer and double entrainer for separating the N-hexane/acetone/chloroform …

C Wang, Y Zhuang, Y Dong, C Zhou, L Zhang… - Chemical Engineering …, 2021 - Elsevier
Currently, there are very limited efforts on investigating triple-column extractive distillation
process with single entrainer (S-TCED) for separating ternary multi-azeotropic mixture with …

Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized …

…, Y Hotko, O Goloborodko, D Chen, M Wang, Z Yu… - Jama, 2022 - jamanetwork.com
Importance Programmed cell death ligand 1 inhibitors combined with chemotherapy has
changed the approach to first-line treatment in patients with extensive-stage small cell lung …

Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled …

…, W Fang, W Wu, G Wang, Y Cheng, Z Yu… - The lancet …, 2021 - thelancet.com
Background Inhibition of vascular endothelial growth factor receptor (VEGFR) has shown
antitumour activity in advanced hepatocellular carcinoma, but few studies of VEGFR inhibitors …

Molecular targeted therapies elicit concurrent apoptotic and GSDME-dependent pyroptotic tumor cell death

…, W Li, J Wang, X Zhao, Z Yu, P Ma, G Zhuang - Clinical Cancer …, 2018 - AACR
Purpose: The induced death signals following oncogene inhibition underlie clinical efficacy
of molecular targeted therapies against human cancer, and defects of intact cell apoptosis …

Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial

…, D Ma, C Wu, Y Cheng, D Chen, W Li, S Sun, Z Yu… - Jama, 2018 - jamanetwork.com
Importance Patients with metastatic colorectal cancer (CRC) have limited effective and
tolerable treatment options. Objective To evaluate the efficacy and safety of oral fruquintinib, a …

[HTML][HTML] AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastaticnon–small-cell lung cancer with …

…, G Zhang, C Liu, J Li, X Yu, Z Lin, Z Yu… - Journal of Clinical …, 2022 - ncbi.nlm.nih.gov
PURPOSE Aumolertinib (formerly almonertinib; HS-10296) is a novel third-generation
epidermal growth factor receptor tyrosine kinase inhibitor approved in China. This double-blind …